CN1440747A - Application of chrysophanic acid and chrysophanate in preparing obesity treating medicine - Google Patents
Application of chrysophanic acid and chrysophanate in preparing obesity treating medicine Download PDFInfo
- Publication number
- CN1440747A CN1440747A CN 03113082 CN03113082A CN1440747A CN 1440747 A CN1440747 A CN 1440747A CN 03113082 CN03113082 CN 03113082 CN 03113082 A CN03113082 A CN 03113082A CN 1440747 A CN1440747 A CN 1440747A
- Authority
- CN
- China
- Prior art keywords
- chrysophanic acid
- group
- chrysophanate
- application
- chrysophanic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Chrysophanic acid and chrysophanate can reduce the weight of db/db mouse and reduce the weight of fat rat with high-fat feed, and may be used in preparing obesity treating medicine.
Description
One. technical field
The present invention relates to chrysophanic acid, specifically, relate to the application of chrysophanic acid in preparation treatment antiobesity agents.
Two. background technology
Obesity is the important cause of disease of diseases such as diabetes, hypertension, cardiovascular and cerebrovascular disease, fatty liver, infertility, insulin resistant.The overweight crowd of China has 200,000,000 at least, and the obese patient reaches 3000-4000 ten thousand.These data are still continuing to increase.Big or the DeGrain of present appetrol side effect.Chrysophanic acid is the isolating product of a kind of natural drug.The report of no relevant chrysophanic acid treatment of obesity at present.
Three. summary of the invention
The objective of the invention is chrysophanic acid is applied to treatment of obesity.
Technical scheme of the present invention is as follows:
The application in preparation treatment of obesity medicine of chrysophanic acid or Radix Et Rhizoma Rhei hydrochlorate.
Chrysophanic acid toxicity is little, and the result shows through the rat acute toxicity test, and the half lethal dose of chrysophanic acid is 3.2g/kg.
The result shows through human experimentation, and chrysophanic acid does not have tangible gastrointestinal reaction.When oral chrysophanic acid dosage 200mg/kg, continuous three days, 36 philtrums had only 5 people that the main suit of gastrointestinal upset is arranged, and wherein 3 people suffer from diarrhoea 2-3 time every day, and only 1 people diarrhoea is above 4 times.
Zoopery shows that oral chrysophanic acid or its salt can alleviate congenital type db/db obesity mice body weight, can alleviate high glucose and high fat diet obese rat body weight.
The dosage of oral chrysophanic acid or its salt suggestion is 25-100mg chrysophanic acid or its salt/day, and it is oral to be divided into 2 times or 3 times.Chrysophanic acid or its salt can be made into capsule or water preparation.Above-mentioned Radix Et Rhizoma Rhei hydrochlorate is chrysophanic acid sodium or chrysophanic acid potassium.
Drug metabolism study is the result show, chrysophanic acid or its salt easily are absorbed by the body, the back blood drug level length of holding time of taking medicine.Single oral 200mg chrysophanic acid, chrysophanic acid concentration peaks in the 1.5-3 hour bleeding from anus, and its blood drug level still remains on the 200-500ng/mL level after 24 hours.Therefore chrysophanic acid or its salt have its superiority as the medicine of treatment of obesity, and it can be prevented and treated by excessive diet and movable the minimizing and cause or congenital type obesity.
The present invention is described by the following examples.Four. specific embodiment embodiment 1 chrysophanic acid alleviates db/db obesity mice body weight.1.1 animal and packet transaction
9 the week age db/db mice be divided into treatment group and non-treatment group, 12 every group at random.Be contrast with db/m mice of the same age simultaneously.Feed with conventional feed the ad lib water inlet.Treatment group mouse feeding chrysophanic acid (120mg/kg dosage is irritated stomach, with the preparation of 0.5% carboxymethyl cellulose normal saline) is fed with 0.5% sodium carboxymethyl cellulose normal saline in contrast for all the other two groups, once a day, and continuous 12 weeks.1.2 result
The db/db mice is a kind of congenital type obesity mice.The birth back obesity promptly occurs at 5-6 week, and body weight continues to increase, and is very obvious when 9 weeks.6 weeks behind the db/db mice administration chrysophanic acid, compare with not treatment group, there were significant differences for body weight; In 9 weeks after the administration, be highly significant difference.(seeing Table 1) table 1: db/db mice body weight change after the chrysophanic acid administration (X ± SD)
After 0w after the administration (g) administration after 6w (g) administration after 9w (g) administration 12w (g) db/m mice 19.2 ± 1.5 24.9 ± 1.2 28.2 ± 0.3 30.5 ± 0.5 (n=10) db/db mice 29.1 ± 2.4**, 42.1 ± 1.4**, 47.2 ± 2.2**, 49.2 ± 1.8** (n=10) db/db mice add 29.5 ± 1.7 38.9 ± 1.7
41.0 ± 1.0
42.1 ± 1.4
Chrysophanic acid feed group (n=10) *: expression is organized relatively P value＜0.05. * * with db/m: expression is compared P value＜0.01. with the db/m group
: expression is compared P value＜0.05. with the db/db group
: expression is compared P value＜0.01. embodiment 2 chrysophanic acids with the db/db group and is alleviated high glucose and high fat diet obese rat body weight.2.1 animal and packet transaction
Cleaning level inbred line female Wistar rats, heavily about 200g is divided into three groups of A (n=10), B (n=10), C (n=10) at random, the ad lib water inlet.The A group is fed with conventional feed, and B and C group are fed with high glucose and high fat feedstuff (20% sucrose, 10% Adeps Sus domestica, 70% conventional feed).All around, C group beginning feeding chrysophanic acid (100mg/kg dosage is irritated stomach, with the preparation of 0.5% carboxymethyl cellulose normal saline), A, B group is fed with 0.5% sodium carboxymethyl cellulose normal saline in contrast, once a day, continuous three weeks.2.2 result
After around the high glucose and high fat diet, the body weight and the A of B and C group organize apparent in view increase.After this explanation high glucose and high fat diet, induced the rat obesity.The chrysophanic acid feeding is after three weeks, and the body weight of C group will obviously lower than the B group.(seeing Table 2) table 2: rat body weight variation before and after chrysophanic acid is handled (X ± SD)
The high glucose and high fat diet is during the 7th week in the time of around the high glucose and high fat diet
Body weight (g) A group (n=10) 11.2 ± 5.09 19.7+4.65B group (n=10) 16.7 ± 2.4* 30.4 ± 3.68*C group (n=10) 16.7 ± 2.4* 16.9 ± 5.01 that the body weight (g) that increases increases
*: expression is compared P value＜0.05. with the conventional feed group
: expression is compared P value＜0.05. with high glucose and high fat diet group
Among the above embodiment, chrysophanic acid uses chrysophanic acid sodium instead or chrysophanic acid potassium substitutes, and obtains identical result.
Claims (1)
1. chrysophanic acid or the Radix Et Rhizoma Rhei hydrochlorate application in preparation treatment of obesity medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113082 CN1440747A (en) | 2003-03-31 | 2003-03-31 | Application of chrysophanic acid and chrysophanate in preparing obesity treating medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113082 CN1440747A (en) | 2003-03-31 | 2003-03-31 | Application of chrysophanic acid and chrysophanate in preparing obesity treating medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1440747A true CN1440747A (en) | 2003-09-10 |
Family
ID=27770375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03113082 Pending CN1440747A (en) | 2003-03-31 | 2003-03-31 | Application of chrysophanic acid and chrysophanate in preparing obesity treating medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1440747A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2003966A2 (en) * | 2006-04-07 | 2008-12-24 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
| CN106038522A (en) * | 2015-10-16 | 2016-10-26 | 北京冠瑞金生物科技有限公司 | Application of rhein in preparation of anti-depression medicines |
-
2003
- 2003-03-31 CN CN 03113082 patent/CN1440747A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2003966A2 (en) * | 2006-04-07 | 2008-12-24 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
| JP2009522378A (en) * | 2006-04-07 | 2009-06-11 | サンテン フィトテック カンパニー，リミテッド | Anthracenedione compounds |
| EP2003966A4 (en) * | 2006-04-07 | 2010-07-07 | Sunten Phytotech Co Ltd | Anthracenedione compounds |
| US7767719B2 (en) | 2006-04-07 | 2010-08-03 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
| US8466202B2 (en) | 2006-04-07 | 2013-06-18 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
| CN106038522A (en) * | 2015-10-16 | 2016-10-26 | 北京冠瑞金生物科技有限公司 | Application of rhein in preparation of anti-depression medicines |
| CN106038522B (en) * | 2015-10-16 | 2019-08-16 | 北京冠瑞金生物科技有限公司 | Rhein is preparing the purposes in anti-depression drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI405576B (en) | Therapeutic agent for painful disease | |
| JPH07507569A (en) | How to promote nitrogen retention in humans | |
| CN1395936A (en) | Health-care food for protecting gastric mucosa and its preparing process | |
| CN1762441A (en) | Chinese medicine composition for treating hyperlipemia and preparing method thereof | |
| CN1440747A (en) | Application of chrysophanic acid and chrysophanate in preparing obesity treating medicine | |
| JP2010111646A (en) | Treating agent for ulcerative colitis | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN105693715A (en) | Preparation and medical application of diacerein berberine conjugate | |
| CN103054932B (en) | Principal columns of a hall tree extract is preparing the application in treating Gastric Ulcer Treatment | |
| CN112457423B (en) | Natural extracted compound polysaccharide with function of improving insulin resistance and application thereof | |
| Azhar et al. | Therapeutic effect of mango seed extract in diabetes mellitus. | |
| JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
| CN1127951C (en) | Application of rhein in treating insulin resistance | |
| CN1319393A (en) | Application of chrysophanic acid in curing hyperlipemia | |
| JP2001048802A (en) | Health auxiliary food effective for diabetes, method of using the same and food combination preparation effective for diabetes | |
| CN108703946B (en) | A kind of transdermal absorption formulation for treating diabete peripheral herve pain | |
| CN102283834B (en) | Orlisat-containing medicinal composition and application thereof | |
| CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| JP2009057336A (en) | Wound-healing promoting composition comprising extract of momordica grosvenori and its application method | |
| JP2022511544A (en) | Chinese herbal medicine composition for bowel movement, its preparation method and its use | |
| JP4611775B2 (en) | Antihypertensive | |
| CN116570611B (en) | Application of anthropomorphic ginsenoside F11 in preparation of medicine for treating chronic kidney diseases | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN101053595B (en) | Medicinal preparation for treating constipation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |